- Home
- GLTO vs NBY Comparison
GLTO vs NBY Comparison
Compare GLTO & NBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- NBY
- Stock Information
- Founded
- GLTO 2011
- NBY 2000
- Country
- GLTO Denmark
- NBY United States
- Employees
- GLTO N/A
- NBY N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- NBY
- Sector
- GLTO Health Care
- NBY
- Exchange
- GLTO Nasdaq
- NBY Nasdaq
- Market Cap
- GLTO 4.4M
- NBY 3.5M
- IPO Year
- GLTO 2020
- NBY 2007
- Fundamental
- Price
- GLTO $3.35
- NBY $0.60
- Analyst Decision
- GLTO Buy
- NBY Strong Buy
- Analyst Count
- GLTO 1
- NBY 1
- Target Price
- GLTO $10.00
- NBY $0.85
- AVG Volume (30 Days)
- GLTO 18.8K
- NBY 32.1K
- Earning Date
- GLTO 08-11-2025
- NBY 08-12-2025
- Dividend Yield
- GLTO N/A
- NBY N/A
- EPS Growth
- GLTO N/A
- NBY N/A
- EPS
- GLTO N/A
- NBY 0.57
- Revenue
- GLTO N/A
- NBY $9,781,000.00
- Revenue This Year
- GLTO N/A
- NBY $23.91
- Revenue Next Year
- GLTO N/A
- NBY $32.05
- P/E Ratio
- GLTO N/A
- NBY $1.33
- Revenue Growth
- GLTO N/A
- NBY 20.52
- 52 Week Low
- GLTO $2.01
- NBY $0.36
- 52 Week High
- GLTO $16.07
- NBY $2.47
- Technical
- Relative Strength Index (RSI)
- GLTO 65.19
- NBY 53.58
- Support Level
- GLTO $3.19
- NBY $0.56
- Resistance Level
- GLTO $3.63
- NBY $0.64
- Average True Range (ATR)
- GLTO 0.24
- NBY 0.03
- MACD
- GLTO 0.01
- NBY -0.00
- Stochastic Oscillator
- GLTO 79.37
- NBY 44.44
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About NBY NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.